Whistleblower files lawsuit against CVS Caremark for falsifying drug prices | wkyc.com

In fact, we announced in March (https://cvshealth.com/newsroom/press-releases/cvs-health-kept-drug-price-growth-nearly-flat-and-improved-medication) that in 2017, we kept drug price growth nearly flat for our PBM clients, despite manufacturer price inflation near 10 percent. Annual out-of-pocket costs for PBM members also declined, with three out of four members spending less than $100 out of pocket for their prescriptions, and nearly 90 percent spending less than $300.

But here’s where this really hits home, while this suit involves Medicare patients, the Ohio House is now looking to see if this is also going on in the State’s three billion dollar Medicaid program.

It recently introduced two bills looking into prescription drug pricing. As CVS also oversees the pharmacy benefits for four of the state’s five Medicaid managed care plans.

“This is really just the tip of the iceberg,” says Ciaccia

What’s interesting, especially considering Aetna did not want details of the lawsuit released, and they were ostensibly harmed by this, is that the Aetna and CVS are trying to get approval for a merger.

Read complete article here:

wkyc.com | Whistleblower files lawsuit against CVS Caremark for falsifying drug prices.